Cargando…
Involvement of CYP4F2 in the Metabolism of a Novel Monophosphate Ester Prodrug of Gemcitabine and Its Interaction Potential In Vitro
Compound-3 is an oral monophosphate prodrug of gemcitabine. Previous data showed that Compound-3 was more potent than gemcitabine and it was orally active in a tumor xenograft model. In the present study, the metabolism of Compound-3 was investigated in several well-known in vitro matrices. While re...
Autores principales: | Wang, Yedong, Li, Yuan, Lu, Jia, Qi, Huixin, Cheng, Isabel, Zhang, Hongjian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6100113/ https://www.ncbi.nlm.nih.gov/pubmed/29772747 http://dx.doi.org/10.3390/molecules23051195 |
Ejemplares similares
-
Recent Development of Prodrugs of Gemcitabine
por: Pandit, Bhoomika, et al.
Publicado: (2022) -
Esters of valerenic acid as potential prodrugs
por: Hintersteiner, Juliane, et al.
Publicado: (2014) -
Synthesis, In Vitro and In Vivo Evaluation of the N-ethoxycarbonylmorpholine Ester of Diclofenac as a Prodrug
por: Jilani, Jamal A., et al.
Publicado: (2014) -
Development and Bioorthogonal Activation of Palladium-Labile
Prodrugs of Gemcitabine
por: Weiss, Jason T., et al.
Publicado: (2014) -
Delivery of Gemcitabine Prodrugs Employing Mesoporous Silica Nanoparticles
por: Malfanti, Alessio, et al.
Publicado: (2016)